Loading patent…
AssigneeRibomic Inc.
InventorsAkio SUZUMURA, Jinyan Wang, Takashi Matsui, Sadatoshi Sakuma, Shin Miyakawa, Masatoshi Fujiwara, Yoshikazu Nakamura
Estimating the term…
The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.
1-20. (canceled)
A method for increasing a number of regulatory T cells comprising inhibition of Midkine using an aptamer against Midkine.
A method for increasing a number of regulatory T cells comprising administration of a Midkine inhibitor which is an aptamer of Midkine.
A method for the treatment, prevention or diagnosis of a disease associated with a functional disorder of regulatory T cells comprising inhibition of Midkine by an aptamer against Midkine.
A method for the treatment, prevention or diagnosis of a disease associated with a functional disorder of regulatory T cells consisting of administration of a Midkine inhibitor which is an aptamer against Midkine.
A method for screening a medicament for the treatment or prevention of a disease associated with a functional disorder of regulatory T cells by binding to an expressed Midkine, comprising:
Dependencies are inferred from the claim text.